Nutrigenomics of Zinc Supplementation in Insulin Secretion and Diabetes

• aged 21-70 years
• Amish decent
• genotyping of rs13266634 of SLC30A8 gene
• previously consented to contact for future studies and future use of DNA

Exclusion Criteria:

• Subject is a first-degree relative of another subject with the same SLC30A8 genotype
• diabetes mellitus (by history, treatment or random BG>200 mg;dl)
• gastrointestinal disease causing nausea, vomiting, or diarrhea including inflammatory bowel disease by history.
• rheumatoid arthritis by history
• albumin \< 3.5 g/dL
• hemochromatosis by history
• hematocrit \<34%
• liver disease by history
• alanine aminotransferase or aspartate aminotransferase greater than 2.5 times normal
• renal failure by history
• estimated glomerular filtration rate \< 60 mL/min by MDRD equation
• use of thiazide diuretic and unwilling to discontinue if deemed safe in the opinion of the treating physician and study physician for 1 week prior to protocol initiation
• use of systemic corticosteroid and unwilling to discontinue if deemed safe in the opinion of the treating physician and study physician for 1 week prior to protocol initiation
• use of highly-active antiretroviral medications
• use of antipsychotic medications
• use of quinolone antibiotics
• use of tetracycline antibiotic and unwilling to discontinue if deemed safe in the opinion of the treating physician and study physician for 1 week prior to protocol initiation
• use of chelation therapy in the past month
• unwilling to withdraw from supplements for 1 week prior to the study and throughout study
• abnormal thyroid stimulating hormone (TSH) level
• serious disease precluding participation
• reported pregnancy or positive urine hCG test
• cancer diagnosis in past 2 years
• breastfeeding
• use of denture adhesive